Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients

Biomedicines · 2026 · PMC13297521

Europe PMC

hedged sentences

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

did not reach statistical significancep = 0.084so close (0.05 < p ≤ 0.1)

A similar trend was observed for OS but did not reach statistical significance (HR 4.13, p = 0.084) ( Table 4 ). 4.

also in 111,027 other papers

showed a trendno p-value reported

Compared with patients without PPM1D mutations, mutation carriers showed a trend toward less deep remissions and demonstrated significantly inferior 6-month PFS (43% vs. 85%, p = 0.0272) and 6-month OS (57% vs. 90%, p = 0.0473).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.